Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 484.8m

Basilea Pharmaceutica Valuation

Is BSLN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BSLN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BSLN (CHF40) is trading below our estimate of fair value (CHF44.34)

Significantly Below Fair Value: BSLN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BSLN?

Key metric: As BSLN is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BSLN. This is calculated by dividing BSLN's market cap by their current revenue.
What is BSLN's PS Ratio?
PS Ratio3.3x
SalesCHF 149.02m
Market CapCHF 484.85m

Price to Sales Ratio vs Peers

How does BSLN's PS Ratio compare to its peers?

The above table shows the PS ratio for BSLN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average14.7x
IDIA Idorsia
2.1x53.8%CHF 156.9m
KURN Kuros Biosciences
17.8xn/aCHF 937.4m
MOLN Molecular Partners
29.8x57.8%CHF 179.0m
RLF Relief Therapeutics Holding
8.9xn/aCHF 76.5m
BSLN Basilea Pharmaceutica
3.3x6.5%CHF 484.8m

Price-To-Sales vs Peers: BSLN is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (14.7x).

Price to Sales Ratio vs Industry

How does BSLN's PS Ratio compare vs other companies in the European Biotechs Industry?

38 CompaniesPrice / SalesEstimated GrowthMarket Cap
BSLN 3.3xIndustry Avg. 7.8xNo. of Companies38PS0816243240+
38 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: BSLN is good value based on its Price-To-Sales Ratio (3.3x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is BSLN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BSLN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ratio1.5x

Price-To-Sales vs Fair Ratio: BSLN is expensive based on its Price-To-Sales Ratio (3.3x) compared to the estimated Fair Price-To-Sales Ratio (1.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BSLN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 40.00
CHF 77.25
+93.1%
31.6%CHF 120.00CHF 52.00n/a6
Nov ’25CHF 43.20
CHF 74.87
+73.3%
35.7%CHF 120.00CHF 44.20n/a6
Oct ’25CHF 45.60
CHF 73.20
+60.5%
32.8%CHF 110.00CHF 44.20n/a6
Sep ’25CHF 46.00
CHF 72.37
+57.3%
32.0%CHF 110.00CHF 44.20n/a6
Aug ’25CHF 39.75
CHF 71.20
+79.1%
30.5%CHF 105.00CHF 44.20n/a6
Jul ’25CHF 39.50
CHF 71.20
+80.3%
30.5%CHF 105.00CHF 44.20n/a6
Jun ’25CHF 43.70
CHF 70.58
+61.5%
31.9%CHF 105.00CHF 40.50n/a6
May ’25CHF 39.50
CHF 70.58
+78.7%
31.9%CHF 105.00CHF 40.50n/a6
Apr ’25CHF 37.65
CHF 69.08
+83.5%
30.6%CHF 105.00CHF 40.50n/a6
Mar ’25CHF 35.15
CHF 69.08
+96.5%
30.6%CHF 105.00CHF 40.50n/a6
Feb ’25CHF 33.05
CHF 64.38
+94.8%
24.7%CHF 85.00CHF 40.50n/a4
Jan ’25CHF 35.30
CHF 70.70
+100.3%
26.5%CHF 91.00CHF 40.50n/a5
Dec ’24CHF 34.95
CHF 75.68
+116.5%
19.8%CHF 91.00CHF 57.70n/a4
Nov ’24CHF 35.60
CHF 73.28
+105.9%
20.1%CHF 91.00CHF 52.00CHF 43.206
Oct ’24CHF 41.00
CHF 70.44
+71.8%
21.7%CHF 91.00CHF 52.00CHF 45.607
Sep ’24CHF 48.20
CHF 70.44
+46.1%
21.7%CHF 91.00CHF 52.00CHF 46.007
Aug ’24CHF 43.85
CHF 70.44
+60.6%
21.7%CHF 91.00CHF 52.00CHF 39.757
Jul ’24CHF 42.25
CHF 67.18
+59.0%
21.0%CHF 91.00CHF 52.00CHF 39.506
Jun ’24CHF 45.90
CHF 67.18
+46.4%
21.0%CHF 91.00CHF 52.00CHF 43.706
May ’24CHF 43.20
CHF 72.07
+66.8%
20.8%CHF 91.00CHF 52.00CHF 39.506
Apr ’24CHF 50.10
CHF 74.80
+49.3%
18.4%CHF 91.00CHF 52.00CHF 37.655
Mar ’24CHF 52.40
CHF 68.98
+31.6%
26.2%CHF 91.00CHF 39.90CHF 35.156
Feb ’24CHF 49.00
CHF 73.82
+50.6%
34.7%CHF 120.00CHF 39.90CHF 33.056
Jan ’24CHF 45.80
CHF 69.15
+51.0%
26.2%CHF 91.00CHF 39.90CHF 35.306
Dec ’23CHF 49.75
CHF 68.58
+37.8%
28.9%CHF 91.00CHF 39.90CHF 34.955
Nov ’23CHF 46.75
CHF 74.48
+59.3%
34.4%CHF 120.00CHF 39.90CHF 35.606

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Roche Holding

CHF 205.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

ROG

CHF 255.80

7D

-2.8%

1Y

7.7%

Roche Holding

CHF 205.2b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania.

RO

CHF 269.20

7D

-5.5%

1Y

6.4%

Evotec

€1.5b

Operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.

EVT

€27.76

7D

0%

1Y

0%